DAVITA INC. Business Acquisition, Pro Forma Revenue
DAVITA INC. (DVA) reported Business Acquisition, Pro Forma Revenue of $13.72 billion for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Income Statement › Other Income
us-gaap:BusinessAcquisitionsProFormaRevenue · last filed 2026-02-11
- DAVITA INC. business acquisition, pro forma revenue for the quarter ending 2017-12-31 was -$462.16M.
- DAVITA INC. business acquisition, pro forma revenue for the quarter ending 2017-09-30 was $3.93B, a 2.11% increase year-over-year.
- DAVITA INC. business acquisition, pro forma revenue for the quarter ending 2017-06-30 was $3.90B, a 2.10% increase year-over-year.
- DAVITA INC. business acquisition, pro forma revenue for the quarter ending 2016-12-31 was -$390.89M, a 110.67% decline year-over-year.
- DAVITA INC. business acquisition, pro forma revenue for fiscal 2025 was $13.72B, a 3.91% increase from fiscal 2024.
- DAVITA INC. business acquisition, pro forma revenue for fiscal 2024 was $13.21B, a 4.61% increase from fiscal 2023.
- DAVITA INC. business acquisition, pro forma revenue for fiscal 2023 was $12.63B, a 8.36% increase from fiscal 2022.
- DAVITA INC. business acquisition, pro forma revenue for fiscal 2022 was $11.65B, a 0.47% decline from fiscal 2021.
| Period end | Business Acquisition, Pro Forma Revenue 3 month | Business Acquisition, Pro Forma Revenue 3 month as first filed | Business Acquisition, Pro Forma Revenue 6 month | Business Acquisition, Pro Forma Revenue 6 month as first filed | Business Acquisition, Pro Forma Revenue 9 month | Business Acquisition, Pro Forma Revenue 9 month as first filed | Business Acquisition, Pro Forma Revenue 12 month | Business Acquisition, Pro Forma Revenue 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $13.72B 10-K · filed 2026-02-11 | |||||||
| 2024-12-31 | $13.21B 10-K · filed 2026-02-11 | $13.07B 10-K · filed 2025-02-13 | ||||||
| 2023-12-31 | $12.63B 10-K · filed 2025-02-13 | $12.16B 10-K · filed 2024-02-14 | ||||||
| 2022-12-31 | $11.65B 10-K · filed 2024-02-14 | $11.62B 10-K · filed 2023-02-22 | ||||||
| 2021-12-31 | $11.71B 10-K · filed 2023-02-22 | $11.68B 10-K · filed 2022-02-11 | ||||||
| 2020-12-31 | $11.72B 10-K · filed 2022-02-11 | $11.64B 10-K · filed 2021-02-12 | ||||||
| 2019-12-31 | $11.57B 10-K · filed 2021-02-12 | $11.42B 10-K · filed 2020-02-21 | ||||||
| 2018-12-31 | $11.57B 10-K · filed 2020-02-21 | $11.51B 10-K · filed 2019-02-22 | ||||||
| 2017-12-31 | -$462.16M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $3.46B derived: sum of 2 quarters · filed 2019-02-22 | $7.36B derived: sum of 3 quarters · filed 2019-02-22 | $11.18B 10-K · filed 2019-02-22 | $11.01B 10-K · filed 2018-02-23 | |||
| 2017-09-30 | $3.93B 10-Q · filed 2017-11-07 | $7.83B derived: sum of 2 quarters · filed 2017-11-07 | $11.64B 10-Q · filed 2017-11-07 | |||||
| 2017-06-30 | $3.90B 10-Q · filed 2017-08-01 | $7.68B 10-Q · filed 2017-08-01 | ||||||
| 2016-12-31 | -$390.89M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23 | $3.45B derived: sum of 2 quarters · filed 2018-02-23 | $7.27B derived: sum of 3 quarters · filed 2018-02-23 | $11.08B 10-K · filed 2018-02-23 | $14.88B 10-K · filed 2017-02-24 | |||
| 2016-09-30 | $3.84B 10-Q · filed 2017-11-07 | $3.73B 10-Q · filed 2016-11-02 | $7.66B derived: sum of 2 quarters · filed 2017-11-07 | $11.47B 10-Q · filed 2017-11-07 | $11.15B 10-Q · filed 2016-11-02 | $14.98B derived: sum of 4 quarters · filed 2017-11-07 | ||
| 2016-06-30 | $3.82B 10-Q · filed 2017-08-01 | $3.71B 10-Q · filed 2016-08-08 | $7.58B 10-Q · filed 2017-08-01 | $7.35B 10-Q · filed 2016-08-08 | $11.13B derived: sum of 3 quarters · filed 2017-08-01 | $14.80B derived: sum of 4 quarters · filed 2017-08-01 | ||
| 2016-03-31 | $3.65B 10-Q · filed 2016-05-04 | $7.31B derived: sum of 2 quarters · filed 2017-02-24 | $10.98B derived: sum of 3 quarters · filed 2017-02-24 | $14.51B derived: sum of 4 quarters · filed 2017-02-24 | ||||
| 2015-12-31 | $3.66B derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-24 | $7.32B derived: sum of 2 quarters · filed 2017-02-24 | $10.85B derived: sum of 3 quarters · filed 2017-02-24 | $14.34B 10-K · filed 2017-02-24 | $13.80B 10-K · filed 2016-02-26 | |||
| 2015-09-30 | $3.66B 10-Q · filed 2016-11-02 | $7.19B derived: sum of 2 quarters · filed 2016-11-02 | $10.68B 10-Q · filed 2016-11-02 | |||||
| 2015-06-30 | $3.53B 10-Q · filed 2016-08-08 | $6.92B 10-Q · filed 2016-08-08 | ||||||
| 2015-03-31 | $3.40B 10-Q · filed 2016-05-04 | |||||||
| 2014-12-31 | $13.04B 10-K · filed 2016-02-26 | $12.89B 10-K · filed 2015-02-26 | ||||||
| 2013-12-31 | $12.16B 10-K · filed 2015-02-26 | $11.89B 10-K · filed 2014-02-21 | ||||||
| 2012-12-31 | $10.88B 10-K · filed 2014-02-21 | $10.64B 10-K · filed 2013-03-01 | ||||||
| 2011-12-31 | $5.07B derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-01 | $10.42B 10-K · filed 2013-03-01 | $7.31B 10-K · filed 2012-02-24 | |||||
| 2011-09-30 | $5.35B 10-Q · filed 2011-11-04 | |||||||
| 2010-12-31 | $1.87B derived: 8-K 12 month − 10-Q 9 month · filed 2012-07-06 | $6.98B 8-K · filed 2012-07-06 | ||||||
| 2010-09-30 | $5.12B 10-Q · filed 2011-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| Progyny, Inc. (PGNY) | United States | $1.994B | 28.37 |
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| MANGOCEUTICALS, INC. (MGRX) | United States | $0.010B | -0.43 |